Fumitremorgin C Attenuates Osteoclast Formation and Function
MAPK
NFATc1
fumitremorgin C
osteoclast
osteoporosis
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
10
2019
accepted:
21
02
2020
entrez:
27
3
2020
pubmed:
27
3
2020
medline:
27
3
2020
Statut:
epublish
Résumé
Excessive bone resorption conducted by osteoclasts is considered as the main cause of osteoclast-related bone diseases such as osteoporosis. Therefore, the suppression of excessive osteoclast formation and function is one of the strategies to treat osteoclast-related bone diseases. Fumitremorgin C (Fum) is a mycotoxin extracted from
Identifiants
pubmed: 32210820
doi: 10.3389/fphar.2020.00238
pmc: PMC7076231
doi:
Types de publication
Journal Article
Langues
eng
Pagination
238Informations de copyright
Copyright © 2020 Yuan, Chen, Chen, Wang, Qiu, Cao, Song, Sun, Guo, Tickner, Xu and Zou.
Références
J Mol Histol. 2007 Aug;38(4):341-5
pubmed: 17576525
Nat Med. 2006 Dec;12(12):1403-9
pubmed: 17128270
J Bone Miner Res. 2005 Aug;20(8):1462-71
pubmed: 16007343
J Cell Physiol. 2019 Jul;234(7):11792-11804
pubmed: 30515822
Endocrinology. 2003 Nov;144(11):4999-5005
pubmed: 12960069
Immunol Rev. 2005 Dec;208:126-40
pubmed: 16313345
Planta Med. 2006 Apr;72(5):387-92
pubmed: 16557450
Curr Opin Cell Biol. 1999 Apr;11(2):226-32
pubmed: 10209157
Sci Rep. 2019 Mar 5;9(1):3523
pubmed: 30837587
J Biol Chem. 2004 Oct 29;279(44):45969-79
pubmed: 15304486
Biochem Pharmacol. 2013 Dec 15;86(12):1775-83
pubmed: 24091016
Clin Cancer Res. 2012 Jan 15;18(2):326-35
pubmed: 22031096
Calcif Tissue Int. 2009 Mar;84(3):229-39
pubmed: 19172215
Cell Signal. 2013 Feb;25(2):552-60
pubmed: 23178987
Int J Biol Sci. 2016 Jan 01;12(2):235-45
pubmed: 26884720
J Cell Physiol. 2016 Sep;231(9):1983-93
pubmed: 26754483
J Cell Biochem. 2019 Aug;120(8):12382-12392
pubmed: 30816596
Cell Signal. 2015 Dec;27(12):2325-31
pubmed: 26343857
Exp Cell Res. 2013 Feb 15;319(4):436-46
pubmed: 23246654
Mol Cells. 2015 Mar;38(3):279-84
pubmed: 25666350
J Clin Invest. 2008 Jun;118(6):2088-97
pubmed: 18464930
Am J Physiol Lung Cell Mol Physiol. 2006 Aug;291(2):L257-64
pubmed: 16489119
Molecules. 2018 Mar 08;23(3):
pubmed: 29518052
J Cell Physiol. 2015 Jan;230(1):210-25
pubmed: 24962140
Bone. 2012 Nov;51(5):902-12
pubmed: 22985540
Cell. 2005 Mar 11;120(5):649-61
pubmed: 15766528
J Bone Miner Res. 2000 Nov;15(11):2178-86
pubmed: 11092398
Blood. 2005 Aug 1;106(3):852-9
pubmed: 15817678
J Cell Physiol. 2004 Jul;200(1):99-106
pubmed: 15137062
J Cell Physiol. 2018 Mar;233(3):2502-2512
pubmed: 28771720
J Cell Physiol. 2019 May;234(5):6477-6488
pubmed: 30341897
Theranostics. 2019 Feb 28;9(6):1634-1650
pubmed: 31037128
Int J Oncol. 2006 Nov;29(5):1237-46
pubmed: 17016657
J Bone Miner Res. 2003 Dec;18(12):2159-68
pubmed: 14672351
Cancer Res. 2000 Jan 1;60(1):47-50
pubmed: 10646850
Cancer Res. 1998 Dec 15;58(24):5850-8
pubmed: 9865745
J Exp Med. 2005 Nov 7;202(9):1261-9
pubmed: 16275763
J Bone Miner Res. 2016 May;31(5):964-74
pubmed: 26684711
J Biol Chem. 2010 Feb 19;285(8):5224-31
pubmed: 20037154
Eur J Pharmacol. 2010 Oct 10;644(1-3):41-8
pubmed: 20655304
Cancer Res. 2012 Dec 15;72(24):6393-402
pubmed: 23066034
Bone. 2005 Jan;36(1):159-72
pubmed: 15664014